Drug intelligence / Profile preview

PF-07261271

Development stage: Phase 1
Lead developer: Pfizer
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

PF-07261271 is a bispecific antibody developed by Pfizer for the treatment of inflammatory bowel diseases (IBD). It targets and inhibits both interleukin 12 subunit p40 (IL-12p40) and tumor necrosis factor ligand superfamily member 15 (TL1A), also known as VEGI. By blocking these two pro-inflammatory pathways, the drug aims to reduce inflammation associated with IBD. The agent is administered intravenously or subcutaneously and is currently in Phase I clinical trials for IBD, including ulcerative colitis.

Other names: PF 07261271PF07261271PF-07261271

Targets

TL1A (TNF-like cytokine 1A)IL12B (Interleukin-12/23 p40 subunit)

Beyond the preview

Go deeper on PF-07261271.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-07261271.

Explore the full profile